3 terminated, 2 recruiting, 1 completed, 1 not yet recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 3, Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1 / Phase 2 | Not yet recruiting | Chao Ji | 100 | 2025-10-01 | 2024-10-29 |
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. AB-101, Rituximab, Cyclophosphamide - Rheumatoid Arthritis, Pemphigus Vulgaris | Phase 1 | Recruiting | IRIS Research and Development, LLC | 30 | 2024-05-15 | 2024-09-03 |
| A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) DSG3-CAART, CABA-201 - Pemphigus Vulgaris | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 40 | 2020-09-29 | 2026-10-15 |
| Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs - Pemphigus Foliaceus, Pemphigus Vulgaris | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2017-10-10 | 2024-02-15 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) ALXN1830 - Pemphigus, Pemphigus Vulgaris | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2017-07-18 | 2020-02-05 |
| Safety Study of PI-0824 to Treat Pemphigus Vulgaris PI-0824 - Pemphigus Vulgaris | Phase 1 | Completed | Peptimmune | 15 | 2003-07-01 | 2005-06-24 |
| Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders Hematopoietic stem cell transplantation - Pemphigus | Phase 1 | Terminated | Richard Burt, MD | 1 | 2002-09-01 | 2013-04-08 |
Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Granulomatosis with Polyangiitis (1) · Immune System Diseases (1) · Lupus Erythematosus, Systemic (1) · Skin Diseases, Vesiculobullous (1)
Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Autoimmune Diseases (6) · Immune System Diseases (6) · Skin Diseases, Vesiculobullous (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Arthritis (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1) · Joint Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Musculoskeletal Diseases (1) · Respiratory Tract Diseases (1) · Rheumatic Diseases (1)
Cyclophosphamide (1) · Glucocorticoids (1) · Hematopoietic Stem Cell Transplantation (1) · Rituximab (1) · fludarabine (1) · orilanolimab (1)
Alexion Pharmaceuticals, Inc. (1) · Cabaletta Bio (1) · Chao Ji (1) · IRIS Research and Development, LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Peptimmune (1) · Richard Burt, MD (1)
United States (6)
Anna Haemel, MD (1) · Cabaletta Bio (1) · David Wofsy, M.D. (1) · Guillermo J. Valenzuela, M.D. (1) · Haley Naik, MD,MHSc (1) · Jeffrey Bluestone, Ph.D. (1) · Kathy I. Perez, M.D. (1) · Michael Rosenblum, MD, Ph.D. (1) · Richard Burt, MD (1)